



Effective Date: 04/2024  
Last Approval/Version: 04/2024  
Next Review Due By: 04/2025  
Policy Number: C21453-A

## Anticonvulsant Agents - IL Medicaid Only

### PRODUCTS AFFECTED

Aptom (Eslicarbazepine Acetate Tab); Banzel (Rufinamide Susp); Banzel (Rufinamide Tab); Briviact (Brivaracetam Oral Soln); Briviact (Brivaracetam Tab); carBAMazepine ER (Carbamazepine Cap ER 12HR); Carbatrol (Carbamazepine Cap ER 12HR); Celontin (Methsuximide Cap); cloBAZam (Clobazam Suspension); cloBAZam (Clobazam Tab); clonazepam ODT (Clonazepam Orally Disintegrating); Depakote ER (Divalproex Sodium Tab ER 24 HR); Depakote (Divalproex Sodium Cap Delayed Release Sprinkle); Depakote (Divalproex Sodium Tab Delayed Release); Diacomit (Stiripentol Cap); Diacomit (Stiripentol Packet); Dilantin (Phenytoin Sodium Extended); Dilantin (Phenytoin Chew Tab); Dilantin (Phenytoin Susp); Elepsia XR (Levetiracetam Tab ER 24HR); Epidiolex (Cannabidiol Soln); Eprontia (Topiramate Oral Soln); Felbamate (Felbamate Susp); Felbamate (Felbamate Tab); Felbatol (Felbamate Susp); Felbatol (Felbamate Tab); Fintepla (Fenfluramine HCl Oral); Fycompa (Perampanel Susp); Fycompa (Perampanel Tab); Gabitril (Tiagabine HCl Tab); Keppra (Levetiracetam Oral Soln); Keppra (Levetiracetam Tab); Keppra XR (Levetiracetam Tab ER 24HR); KlonoPIN (Clonazepam Tab); Lacosamide (Lacosamide Tab); LaMICtal (Lamotrigine Tab Chewable Dispersible); LaMICtal (Lamotrigine Tab Disint); LaMICtal ODT (Lamotrigine Orally Disintegrating); LaMICtal (Lamotrigine Tab); LaMICtal XR (Lamotrigine Tab ER 24HR); Lamotrigine ER (Lamotrigine Tab ER 24HR); IamoTRIgine (Lamotrigine Tab); Lamotrigine ODT (Lamotrigine Orally Disintegrating); Mysoline (Primidone Tab); Nayzilam (Midazolam Nasal Spray); Neurontin (Gabapentin Cap); Neurontin (Gabapentin Oral Soln); Neurontin (Gabapentin Tab); Onfi (Clobazam Suspension); Onfi (Clobazam Tab); Oxtellar XR (Oxcarbazepine Tab ER 24HR); Qudexy XR (Topiramate Cap ER 24HR Sprinkle); Rufinamide (Rufinamide Susp); Rufinamide (Rufinamide Tab); Sabril (Vigabatrin Powd Pack); Sabril (Vigabatrin Tab); Spritam (Levetiracetam Tab Disintegrating Soluble); Subvenite KIT (Lamotrigine Tab); Sympazan (Clobazam Oral Film); TEGretol (Carbamazepine Susp); TEGretol (Carbamazepine Tab); TEGretol-XR (Carbamazepine Tab ER 12HR); tiaGABine (Tiagabine HCl Tab); Topamax (Topiramate Sprinkle Cap); Topamax (Topiramate Tab); Topiramate ER (Topiramate Cap ER 24HR Sprinkle); Trileptal (Oxcarbazepine Susp); Trileptal (Oxcarbazepine Tab); Trokendi XR (Topiramate Cap ER 24HR); Valtoco (Diazepam Nasal Spray); Vigabatrin (Vigabatrin Powd Pack); Vigabatrin (Vigabatrin Tab); Vigadrone (Vigabatrin Powd Pack); Vigadrone (Vigabatrin Tab); Vimpat (Lacosamide Oral Solution); Vimpat (Lacosamide Tab); Zarontin (Ethosuximide Cap); Zarontin (Ethosuximide Soln); Zonisade (Zonisamide Susp)

### COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.

### Documentation Requirements:

## Drug and Biologic Coverage Criteria

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes.

Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

### DIAGNOSIS:

Epilepsy or seizure disorder

### REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review

- A. Epilepsy or seizure disorder
  - 1. Documentation that member has a diagnosis of epilepsy or seizure disorder.
- B. ALL OTHER INDICATIONS
  - 1. Review per Illinois Medicaid Medical Necessity Review policy.

### CONTINUATION OF THERAPY:

- A. Epilepsy or seizure disorder
  - 1. Documentation that member has a diagnosis of epilepsy or seizure disorder.
- B. ALL OTHER INDICATIONS
  - 1. Review per Illinois Medicaid Medical Necessity Review policy.

### DURATION OF APPROVAL:

12 months

### PRESCRIBER REQUIREMENTS:

None

### AGE RESTRICTIONS:

Per FDA label

### QUANTITY:

Quantity limit per Illinois Medicaid preferred drug listing.

### PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

The recommendation is that intranasal medications in this policy will be for pharmacy benefit coverage and patient self-administered.

## DRUG INFORMATION

### ROUTE OF ADMINISTRATION:

Molina Healthcare, Inc. confidential and proprietary © 2024

This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Molina Healthcare.

Drug and Biologic Coverage Criteria  
Oral, Intranasal

**DRUG CLASS:**  
Anticonvulsants

**FDA-APPROVED USES:**  
Epilepsy and recurrent seizures

**COMPENDIAL APPROVED OFF-LABELED USES:**  
None

**EXCLUSIONS**

**EXCLUSIONS:**

All other uses of agents listed in this policy are considered experimental/investigational and therefore, will follow Molina's Off- Label policy.

**CODING/BILLING INFORMATION**

*Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement*

HCPCS CODE	DESCRIPTION
NA	

**AVAILABLE DOSAGE FORMS:**

Aptiom TABS 200MG	Carbatrol CP12 300MG	Dilantin CAPS 100MG
Aptiom TABS 400MG	Celontin CAPS 300MG	Dilantin CAPS 30MG
Aptiom TABS 600MG	cloBAZam SUSP 2.5MG/ML	Dilantin Infatabs CHEW 50MG
Aptiom TABS 800MG	cloBAZam TABS 10MG	Dilantin SUSP 125MG/5ML
Banzel SUSP 40MG/ML	cloBAZam TABS 20MG	Elepsia XR TB24 1000MG
Banzel TABS 200MG	clonazePAM TBDP 0.125MG	Elepsia XR TB24 1500MG
Banzel TABS 400MG	clonazePAM TBDP 0.25MG	Epidiolex SOLN 100MG/ML
Briviact SOLN 10MG/ML	clonazePAM TBDP 0.5MG	Eprontia SOLN 25MG/ML
Briviact TABS 100MG	clonazePAM TBDP 1MG	Felbamate SUSP 600MG/5ML
Briviact TABS 10MG	clonazePAM TBDP 2MG	Felbamate TABS 400MG
Briviact TABS 25MG	Depakote ER TB24 250MG	Felbamate TABS 600MG
Briviact TABS 50MG	Depakote ER TB24 500MG	Felbatol SUSP 600MG/5ML
Briviact TABS 75MG	Depakote Sprinkles CSDR	Felbatol TABS 400MG
carBAMazepine ER CP12 100MG	125MG	Felbatol TABS 600MG
carBAMazepine ER CP12 200MG	Depakote TBEC 125MG	Fintepla SOLN 2.2MG/ML
carBAMazepine ER CP12 300MG	Depakote TBEC 250MG	Fycompa SUSP 0.5MG/ML
Carbatrol CP12 100MG	Depakote TBEC 500MG	Fycompa TABS 10MG
Carbatrol CP12 200MG	Diacomit CAPS 250MG	Fycompa TABS 12MG
	Diacomit CAPS 500MG	Fycompa TABS 2MG
	Diacomit PACK 250MG	Fycompa TABS 4MG
	Diacomit PACK 500MG	Fycompa TABS 6MG



## REFERENCES

1. Illinois Medicaid Preferred Drug List, Effective January 1, 2024.
2. The Department of Healthcare and Family Services Law of the Civil Administrative Code of Illinois:  
<https://ilga.gov/legislation/publicacts/101/PDF/101-0209.pdf>

SUMMARY OF REVIEW/REVISIONS	DATE
ANNUAL REVIEW COMPLETED- Notable revisions: Appendix (deleted) Background (deleted) References	04/2024
ANNUAL REVIEW COMPLETED – Updated medications. Minor criteria revisions	Q2/2023
Updated reference to Medical Necessity and deleted Global Clinical Exception Policy	7/2022
ANNUAL REVIEW COMPLETED- No coverage criteria changes with this annual review.	Q2/2022